We first performed qRT-PCR, immunohistochemistry (IHC), and western blot assays to examine mRNA and protein levels of NAF1 in gliomas (n = 30) and normal brain tissues (n = 8; controls). This evidence concerns the gene NAF1 and central nervous system cancer.